24 results for author:"Schuuring E." in Literature citations
Results Customize
› Repeat search in UniProtKB (9)
| The role of ATM and 53BP1 as predictive markers in cervical cancer. Roossink F., Wieringa H.W., Noordhuis M.G., ten Hoor K.A., Kok M., Slagter-Menkema L., Hollema H., de Bock G.H., Pras E., de Vries E.G. et al. Int. J. Cancer 131:2056-2066(2012) · Mapped (6) |
| EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. Thunnissen E., Bovee J.V., Bruinsma H., van den Brule A.J., Dinjens W., Heideman D.A., Meulemans E., Nederlof P., van Noesel C., Prinsen C.F. et al. J. Clin. Pathol. 64:884-892(2011) · Mapped (26) |
| A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Eijsink J.J., Lendvai A., Deregowski V., Klip H.G., Verpooten G., Dehaspe L., de Bock G.H., Hollema H., van Criekinge W., Schuuring E. et al. Int. J. Cancer 130:1861-1869(2012) · Mapped (5) |
| Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Noordhuis M.G., Fehrmann R.S., Wisman G.B., Nijhuis E.R., van Zanden J.J., Moerland P.D., Ver Loren van Themaat E., Volders H.H., Kok M., ten Hoor K.A. et al. Clin. Cancer Res. 17:1317-1330(2011) · Mapped (19) |
| The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Eijsink J.J., Noordhuis M.G., ten Hoor K.A., Kok M., Hollema H., de Bock G.H., Nijman H.W., Schuuring E., Wisman G.B., van der Zee A.G. Hum. Pathol. 41:1735-1741(2010) · Mapped (19) |
| CD44 expression predicts local recurrence after radiotherapy in larynx cancer. de Jong M.C., Pramana J., van der Wal J.E., Lacko M., Peutz-Kootstra C.J., de Jong J.M., Takes R.P., Kaanders J.H., van der Laan B.F., Wachters J. et al. Clin. Cancer Res. 16:5329-5338(2010) · Mapped (6) |
| Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Noordhuis M.G., Eijsink J.J., Ten Hoor K.A., Roossink F., Hollema H., Arts H.J., Pras E., Maduro J.H., Reyners A.K., de Bock G.H. et al. Clin. Cancer Res. 15:7389-7397(2009) · Mapped (19) |
| Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Yang N., Eijsink J.J., Lendvai A., Volders H.H., Klip H., Buikema H.J., van Hemel B.M., Schuuring E., van der Zee A.G., Wisman G.B. Cancer Epidemiol. Biomarkers Prev. 18:3000-3007(2009) · Mapped (7) |
| Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Wisman G.B., Nijhuis E.R., Hoque M.O., Reesink-Peters N., Koning A.J., Volders H.H., Buikema H.J., Boezen H.M., Hollema H., Schuuring E. et al. Int. J. Cancer 119:1908-1914(2006) · Mapped (2) |
| The relationship between HLA class II polymorphisms and somatic deletions in testicular B cell lymphomas of Dutch patients. Riemersma S.A., Jordanova E.S., Haasnoot G.W., Drabbels J., Schuuring E., Schreuder G.M., Kluin P.M. Hum. Immunol. 67:303-310(2006) · Mapped (481) |
| Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. van Rossum A.G., Moolenaar W.H., Schuuring E. Exp. Cell Res. 312:1658-1670(2006) · Mapped (5) |
| H2AX is not affected in mantle cell lymphoma with 11q23 deletion. Guikema J.E., de Boer-Bergsma R.W., Akkermans K., Schuuring E., Kluin P.M. Genes Chromosomes Cancer 45:426-427(2006) · Mapped (1) |
| Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. van Rossum A.G., Gibcus J., van der Wal J., Schuuring E. Breast Cancer Res. 7:235-237(2005) · Mapped (5) |
| Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Specht K., Haralambieva E., Bink K., Kremer M., Mandl-Weber S., Koch I., Tomer R., Hofler H., Schuuring E., Kluin P.M. et al. Blood 104:1120-1126(2004) · Mapped (5) |
| Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. von Bergh A.R.M., Wijers P.M., Groot A.J., van Zelderen-Bhola S., Falkenburg J.H.F., Kluin P.M., Schuuring E. Genes Chromosomes Cancer 39:324-334(2004) · UniProtKB (2) |
| EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin S.-F., Milner J., Brown L.A., Hsu F., Gilks B. et al. |
| Alternative splicing of the actin binding domain of human cortactin affects cell migration. van Rossum A.G., de Graaf J.H., Schuuring-Scholtes E., Kluin P.M., Fan Y.X., Zhan X., Moolenaar W.H., Schuuring E. J. Biol. Chem. 278:45672-45679(2003) · Mapped (8) |
| Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Kuiper R.P., Schepens M., Thijssen J., van Asseldonk M., van den Berg E., Bridge J., Schuuring E., Schoenmakers E.F., van Kessel A.G. Hum. Mol. Genet. 12:1661-1669(2003) · UniProtKB (1) |
| Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Jordanova E.S., Riemersma S.A., Philippo K., Schuuring E., Kluin P.M. Int. J. Cancer 103:393-398(2003) · Mapped (7) |
| LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia. von Bergh A.R., Beverloo H.B., Rombout P., van Wering E.R., van Weel M.H., Beverstock G.C., Kluin P.M., Slater R.M., Schuuring E. Genes Chromosomes Cancer 35:92-96(2002) · Mapped (4) |
| Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Janssen J.W.G., Vaandrager J.W., Heuser T., Jauch A., Kluin P.M., Geelen E., Bergsagel P.L., Kuehl W.M., Drexler H.G., Otsuki T. et al. Blood 95:2691-2698(2000) · UniProtKB (1) |
| The redistribution of cortactin into cell-matrix contact sites in human carcinoma cells with 11q13 amplification is associated with both overexpression and post-translational modification. van Damme H., Brok H., Schuuring-Scholtes E., Schuuring E. J. Biol. Chem. 272:7374-7380(1997) |
| The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Schuuring E.M.D., Verhoeven E., Litvinov S., Michalides R.J.A. Mol. Cell. Biol. 13:2891-2898(1993) · UniProtKB (1) |
| Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Schuuring E.M.D., Verhoeven E., Mooi W.J., Michalides R.J.A. Oncogene 7:355-361(1992) · UniProtKB (1) |